- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03067935
Individual Patient Expanded Access-Glembatumumab Vedotin
May 17, 2018 updated by: Celldex Therapeutics
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.
Study Overview
Status
No longer available
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient is 18 years of age or older.
- The patient has histologically confirmed, gpNMB expressing, metastatic triple-negative breast cancer
- Overexpression of gpNMB in at least one tumor sample as determined by a Sponsor approved laboratory using IHC methods
- The patient does not have abnormal organ function, active autoimmune disease, active infections or additional concurrent conditions that would compromise the patient's ability to safely receive glembatumumb vedotin.
- The patient is not eligible for or cannot access ongoing glembatumumab vedotin clinical trials
- The patient does not qualify for, or cannot access, other comparable or satisfactory alternative therapy for triple negative breast cancer.
- The patient is able to read and understand, and has signed a patient informed consent form, which outlines the nature of the proposed treatment and the anticipated benefits and risks of treatment with glembatumumab vedotin.
Exclusion Criteria:
- History of allergic reactions attributed to compounds of similar composition to glembatumumab vedotin, MMAE, dolastatin or auristatin.
- Pregnant or breast-feeding women, and women or men who are not willing to use effective contraception during the time from signing of informed consent through two months after the last dose of glembatumumab vedotin treatment.
- The patient was previously treated with glembatumumab vedotin or previously enrolled on the METRIC trial (regardless of which arm they were randomized to).
- Any underlying medical condition that, in the investigator's or Sponsor's opinion, will make the administration of Glembatumumab vedotin hazardous to the patient, or would obscure the interpretation of adverse events.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
February 23, 2017
First Submitted That Met QC Criteria
February 28, 2017
First Posted (Actual)
March 1, 2017
Study Record Updates
Last Update Posted (Actual)
May 21, 2018
Last Update Submitted That Met QC Criteria
May 17, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Glembatumumab vedotin CU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic gpNMB Expressing Triple Negative Breast Cancer
-
Celldex TherapeuticsCompletedMetastatic gpNMB Over-expressing Triple Negative Breast CancerUnited States, France, Spain, Italy, Canada, Germany, Australia, Belgium, United Kingdom
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Western Regional Medical CenterWithdrawnMetastatic Non-Small Cell Lung Cancer | Metastatic Colon Cancer | Metastatic Triple Negative Breast CancerUnited States
-
Huihua XiongNot yet recruitingMetastatic Triple-negative Breast CancerChina
-
PharmAbcineMerck Sharp & Dohme LLCRecruitingMetastatic Triple-Negative Breast CancerAustralia
-
Gilead SciencesParexel; IQVIA RDS (Shanghai) Co., Ltd.; Medidata Solutions; Q Squared Solutions...Active, not recruitingMetastatic Triple-negative Breast CancerChina
-
Yale UniversityIovance Biotherapeutics, Inc.CompletedMetastatic Triple Negative Breast CancerUnited States
Clinical Trials on glembatumumab vedotin
-
Celldex TherapeuticsTerminated
-
PrECOG, LLC.Celldex TherapeuticsTerminatedStudy of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung (PrE0504)Squamous Cell Carcinoma of the LungUnited States
-
University of VirginiaCelldex TherapeuticsWithdrawn
-
CuraGen CorporationCompletedBreast CancerUnited States
-
CuraGen CorporationCompletedUnresectable Stage III or Stage IV MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Uveal Melanoma AJCC v7 | Recurrent Uveal MelanomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent OsteosarcomaUnited States, Canada, Puerto Rico
-
Celldex TherapeuticsCompletedBreast CancerUnited States
-
National Cancer Institute (NCI)WithdrawnMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions
-
Tianjin Medical University Second HospitalRecruitingHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaChina